Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, announces the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. “The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments,” said Kevin Ali, Chief Executive Officer of Organon.
Read the full article: Organon Completes Acquisition of Dermavant //
Source: https://www.businesswire.com/news/home/20241028071253/en/Organon-Completes-Acquisition-of-Dermavant-including-Innovative-Dermatologic-Therapy-VTAMA%C2%AE-tapinarof-Cream-1